If your interest in intimacy has quietly drifted over the last few years, you're not imagining it, and you're not alone. Before you consider any physician-guided option like PT-141 (bremelanotide), there's one practical conversation worth understanding first: what it can do to your blood pressure, and what to tell a provider before you begin.

Desire changes are real, and so are the questions

Shifts in desire around perimenopause and menopause are common and legitimate to raise with a clinician. They can involve hormones, sleep, stress, relationship dynamics, mood, medications, or a mix of all of these at once. Wanting closeness at 47 or 58 is not something to feel awkward about. What makes a difference is talking to a provider who treats desire as a real health topic and who can help sort out what's driving the change.

One option a provider may discuss for certain premenopausal women is bremelanotide, a melanocortin-receptor agonist. It's worth understanding how it works, and why blood pressure comes up in that conversation.

What PT-141 (bremelanotide) actually is

Bremelanotide is not a hormone and not a blood-flow drug like the ones marketed to men. It's a peptide that activates melanocortin receptors in the central nervous system [1]. The U.S. Food and Drug Administration approved a brand-name bremelanotide injection for hypoactive sexual desire disorder (HSDD) in premenopausal women [2]. That approval matters because it means the molecule has been studied through a formal regulatory process.

A note on formulations: bremelanotide is also sometimes discussed as a compounded product. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.

Key regulatory facts about bremelanotide
2019FDA approval yearFor HSDD in premenopausal women
Melanocortin receptor agonistDrug classNot a hormone
Premenopausal womenApproved populationPer FDA labeling

Source: [2] FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women, [3] Vyleesi (bremelanotide) Prescribing Information — FDA Label (DailyMed)

Why blood pressure is the headline safety topic

Here's the part a good provider will not skip. Because melanocortin receptors also influence the cardiovascular system, bremelanotide can cause a transient rise in blood pressure and a corresponding drop in heart rate after each use [1][3]. The FDA-approved labeling describes these increases as temporary, typically occurring in the hours after administration and resolving afterward [3].

That's manageable for some people and a genuine reason for caution in others. The label specifically advises against use in people with uncontrolled high blood pressure or known cardiovascular disease, and it notes the drug is not recommended in those at high risk for cardiovascular disease [3]. This is exactly why a provider reviews your blood pressure history before considering it, not after.

Flushing is the other effect worth expecting in the conversation. Along with nausea, flushing was among the most commonly reported side effects in the clinical program [3]. It's usually described as temporary, but it's the kind of thing you'd want to know about in advance rather than be surprised by.

How the transient effects are described (no dosing)
1After useTemporary rise in blood pressure, drop in heart rate
2Hours laterFlushing and nausea most commonly reported
3ResolutionBlood-pressure changes described as transient

Source: [3] Vyleesi (bremelanotide) Prescribing Information — FDA Label (DailyMed)

What to disclose before you try it

Think of this as the checklist a thoughtful provider will walk through with you. Being ready with honest answers makes the visit faster and safer.

  • Your blood pressure history. Whether it runs high, whether it's controlled, and what your recent readings have been. Uncontrolled hypertension is a red flag the label calls out directly [3].
  • Any heart or vascular conditions. Prior heart disease, or a strong risk profile, changes the calculus [3].
  • Every medication and supplement you take — including anything for blood pressure. Bremelanotide's labeling notes it may slow the absorption of certain oral medications, which is a reason your full list matters [3].
  • Whether you are pregnant, may become pregnant, or are breastfeeding.
  • Your menopausal status. The FDA approval is specifically for premenopausal women [2], so if you're postmenopausal, this is an essential thing to raise; a provider will explain what that means for you and what other paths exist.

None of this is about disqualifying you. It's about matching the right person to the right option — and sometimes the answer is a different approach entirely.

Cautions named in the FDA label
Uncontrolled hypertensionAdvised againstPer FDA labeling
Known cardiovascular diseaseAdvised againstPer FDA labeling
High CV riskNot recommendedPer FDA labeling

Source: [3] Vyleesi (bremelanotide) Prescribing Information — FDA Label (DailyMed)

When to call a provider

General, educational guidance — not a substitute for your clinician's instructions. Reach out promptly if, after use, you notice a severe or persistent headache, chest pain or pressure, a very slow or pounding heartbeat, vision changes, or symptoms of dangerously high blood pressure. Because the effect on blood pressure is real, some providers ask patients to know their baseline readings before starting [3]. If anything feels alarming, treat it as urgent and seek care.

Is this even the right question for me?

Maybe, maybe not — and that's the honest answer. Faded desire can trace back to thyroid function, iron levels, sleep, mood, relationship stress, or the hormonal shifts of the menopause transition [4][5]. A single peptide is not the universal answer, and a responsible evaluation usually starts with understanding *why* things changed before deciding *what*, if anything, to do about it. That's why lab work and a real conversation come before any prescription.

A prescription is never guaranteed. Whether any medication is appropriate is a decision made by an independent licensed provider based on your history and evaluation. This article is educational and is not medical advice.

Where Velri fits

Velri is a technology and coordination company — not a medical provider. We help make the process less intimidating by coordinating the pieces: lab work to help understand what's behind the change, a visit with an independent, licensed provider who can talk with you as an adult about desire and safety, and — only if that provider decides it's appropriate — fulfillment through an independent, licensed pharmacy. Care is provided by independent provider groups; medications are dispensed by independent pharmacies. Whether treatment is right for you, and what it should be, is always the provider's call, not ours.